

Supplementary information for “Estimating antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling”

Stacey S CHERNY^{1,2}, Daniel NEVO³, Avi BARAZ^{1,2,3}, Shoham BARUCH^{1,2}, Ohad LEWIN-EPSTEIN⁴, Gideon Y STEIN^{5,6}, Uri OBOLSKI^{1,2,*}

¹School of Public Health, Tel Aviv University, Tel Aviv, Israel

²Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel

³Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel

⁴Department of Molecular Biology and Ecology of Plants, Tel Aviv University, Tel Aviv, Israel


⁵Internal Medicine “A”, Meir Medical Center, Kfar Saba, Israel

⁶Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

*to whom correspondence should be addressed: uriobols@tauex.tau.ac.il

Illustrative example

To facilitate the intuition regarding the utility of ABN modelling for evaluating cross-resistance patterns, we suggest a simple example: Suppose we measure four variables: nosocomial status (Nos) and resistance to three antibiotics (a1, a2, a3). Further assume the following causal structure: high levels of usage of the first antibiotic in the hospital cause nosocomial bacteria to be more resistant to it, whereas the second and third antibiotics are rarely used in the hospital. Further assume that a mutation conferring resistance to the first antibiotic has a probability p to cause resistance to the two other antibiotics. Say we were to analyze these models using logistic regression. We would have trouble even formulating a model in terms of exposure and outcome variables due to the trivariate nature of the outcome. Any such model would force either two of the antibiotics as exposure variables, or require several univariate models, and correct inclusion of the Nos variable in the models would also not be trivial. Hence, such models would struggle to provide a complete picture of the dependency structure at hand. However, using ABN we would discover the following network:



Hence, this form of modelling could reveal cross-resistance patterns, while taking into account causal drivers of individual, and mutual, resistance patterns.

Table S1: The maximum number of parents sufficient to reach the maximum likelihood seen, the number of arcs in this model, and the number of arcs present in at least 50% of the simulations, representing the final models presented, for each of the 5 bacteria analyzed.

Bacteria	Max parents needed	Initial # of arcs	Arcs in 50% of simulations
<i>Escherichia coli</i>	4	23	21
<i>Klebsiella pneumoniae</i>	3	10	10
<i>Pseudomonas aeruginosa</i>	4	12	12
<i>Proteus mirabilis</i>	3	17	17
<i>Staphylococcus coag. neg. group</i>	4	26	18

Table S2: *Escherichia coli* OR estimates and their 95% credible intervals. None of the credible intervals contains unity.

Variable Affected by	2.5%	OR	97.5%
T.F.aminoglycoside Sex	2.18	3.24	4.79
T.F.fluoroquinolone Sex	1.69	2.27	3.04
T.F.betalactam Sex	1.92	2.48	3.18
T.F.other Age	0.69	0.79	0.90
T.F.other Sex	1.64	2.13	2.76
Hosp T.F.aminoglycoside	1.20	1.38	1.58
Hosp T.F.fluoroquinolone	1.57	1.77	1.98
Hosp T.F.betalactam	1.56	1.74	1.94
Hosp T.F.other	1.64	1.84	2.06
Nosocomial T.F.aminoglycoside	0.23	0.39	0.60
Nosocomial Hosp	2.75	3.36	4.17
Poly T.F.betalactam	1.87	2.66	3.82
Poly Nosocomial	1.64	2.34	3.30
AMP CIP	10.45	17.51	32.46
CIP Sex	1.46	1.93	2.51
CIP T.F.fluoroquinolone	1.72	2.47	3.55
CIP Hosp	1.23	1.44	1.67
GEN T.F.other	1.34	1.89	2.64
GEN CIP	5.58	8.39	13.30
Sulf-Trim CIP	4.58	6.14	8.19
Sulf-Trim GEN	1.97	2.95	4.51

Note: Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hosp = $\log(\text{days hospitalized} + 1)$; Poly = polymicrobial culture; AMP = ampicillin; CIP = ciprofloxacin; GEN = gentamicin; Sulf-Trim = sulfamethoxazole-trimethoprim.

Table S3: *Klebsiella pneumoniae* OR estimates and their 95% credible intervals. None of the credible intervals contains unity.

Variable Affected by	2.5%	OR	97.5%
T.F.other Age	0.60	0.72	0.84
Hosp T.F.aminoglycoside	1.31	1.53	1.78
Hosp T.F.betalactam	2.00	2.32	2.68
Hosp T.F.other	1.57	1.80	2.06
Nosocomial Hosp	2.19	2.70	3.38
Poly Nosocomial	2.06	2.90	4.09
AMK CIP	6.06	12.90	35.65
CIP T.F.other	1.50	2.16	3.09
CIP GEN	5.10	7.46	11.12
GEN Hosp	1.28	1.52	1.80

Note: Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hosp = log(days hospitalized + 1); Poly = polymicrobial culture; AMK = amikacin; CIP = ciprofloxacin; GEN = gentamicin.

Table S4: *Pseudomonas aeruginosa* OR estimates and their 95% credible intervals. None of the credible intervals contains unity.

Variable Affected by	2.5%	OR	97.5%
Hosp T.F.aminoglycoside	1.21	1.44	1.70
Hosp T.F.fluoroquinolone	1.14	1.34	1.56
Hosp T.F.betalactam	1.82	2.19	2.61
Hosp T.F.other	1.52	1.79	2.10
Nosocomial T.F.fluoroquinolone	0.28	0.45	0.69
Nosocomial Hosp	2.37	2.97	3.82
Poly Nosocomial	1.43	2.03	2.88
CAZ Sex	1.37	2.45	4.74
CAZ Nosocomial	1.48	2.62	4.88
GEN CAZ	4.71	8.28	14.46
IPM CAZ	2.24	4.15	7.51
IPM GEN	2.09	3.79	6.71

Note: Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hosp = $\log(\text{days hospitalized} + 1)$; Poly = polymicrobial culture; CAZ = ceftazidime; GEN = gentamicin; IPM = imipenem.

Table S5: *Proteus mirabilis* OR estimates and their 95% credible intervals. None of the credible intervals contains unity.

Variable Affected by	2.5%	OR	97.5%
Age Sex	0.55	0.69	0.84
T.F.aminoglycoside Sex	1.51	2.59	4.68
T.F.betalactam Sex	1.73	2.68	4.16
T.F.other Sex	1.51	2.35	3.59
Hosp T.F.aminoglycoside	1.31	1.57	1.86
Hosp T.F.betalactam	1.54	1.85	2.20
Hosp T.F.other	1.91	2.27	2.69
Nosocomial Hosp	2.46	3.20	4.32
Poly Nosocomial	2.05	3.09	4.68
CXM T.F.other	2.16	3.26	4.95
CIP Poly	0.17	0.29	0.45
CIP CXM	4.00	6.28	10.19
GEN CXM	7.47	12.44	21.57
GEN CIP	2.80	4.71	8.04
Sulf-Trim T.F.other	1.50	2.45	4.07
Sulf-Trim CIP	1.51	2.57	4.38
Sulf-Trim GEN	3.51	5.96	10.58

Note: Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hosp = $\log(\text{days hospitalized} + 1)$; Poly = polymicrobial culture; CXM = cefuroxime; CIP = ciprofloxacin; GEN = gentamicin; Sulf-Trim = sulfamethoxazole-trimethoprim.

Table S6: *Staphylococcus* coag. neg. group OR estimates and their 95% credible intervals. None of the credible intervals contains unity.

Variable Affected by	2.5%	OR	97.5%
T.F.aminoglycoside Sex	1.31	2.15	3.56
T.F.betalactam Age	0.58	0.71	0.86
T.F.other Age	0.53	0.65	0.79
Hosp T.F.aminoglycoside	1.36	1.65	1.98
Hosp T.F.fluoroquinolone	1.29	1.52	1.78
Hosp T.F.betalactam	1.67	1.98	2.33
Hosp T.F.other	1.35	1.59	1.86
Nosocomial Hosp	2.66	3.42	4.48
CHL OFX	5.13	7.72	12.03
ERY OFX	5.80	8.94	14.06
Fusid OXA	2.88	4.64	7.73
GEN T.F.aminoglycoside	1.51	2.57	4.42
GEN OFX	5.09	8.04	13.48
OFX T.F.fluoroquinolone	1.49	2.52	4.37
OFX Hosp	1.69	2.11	2.64
OXA OFX	9.90	18.77	40.75
OXA Sulf-Trim	5.22	10.51	24.46
Sulf-Trim OFX	6.11	9.27	14.35

Note: Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hosp = log(days hospitalized + 1); Poly = polymicrobial culture; CHL = chloramphenicol; ERY = erythromycin; Fusid = fusidic acid; GEN = gentamicin; OFX = ofloxacin; OXA = oxacillin; Sulf-Trim = sulfamethoxazole-trimethoprim.

Figure S1: Consistency matrix showing proportion of models which contain a given arc. Each cell contains the proportion of models containing both variables and having a direct link between them (negative representing $OR < 1$). Color represents proportion of datasets containing the arc and the sign of the relationship. All signs of links were consistent across the datasets and shown in the figure. Sex = male; T.F. prefix denotes having taken an antibiotic from the given class; Hospitalized = $\text{Log}(\text{Days Hospitalized} + 1)$; AMK = amikacin; AMP = ampicillin; CAZ = ceftazidime; CXM = cefuroxime; CHL = chloramphenicol; CIP = ciprofloxacin; ERY = erythromycin; Fusid = fusidic acid; GEN = gentamicin; IPM = imipenem; OFX = ofloxacin; OXA = oxacillin; Sulf-Trim = sulfamethoxazole-trimethoprim.

Sulf-Trim -	0/3	0/3	0/3	0/3	0/3	1/3	0/3	0/3	0/3	0/0	0/1	0/0	0/1	0/1	2/2	0/1	0/1	2/3	0/0	1/1	1/1	
OXA -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	0/1	0/0	0/1	1/1	0/1	0/0	1/1		1/1
OFX -	0/1	0/1	0/1	0/1	1/1	0/1	1/1	0/1	0/1	0/0	0/0	0/0	0/0	1/1	0/0	1/1	0/1	1/1	0/0	1/1	1/1	1/1
IPM -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	1/1	0/0	0/0	0/0	0/0	1/1			0/0	0/0	0/0
GEN -	0/5	0/5	1/5	0/5	0/5	1/5	1/5	0/5	0/5	0/1	0/1	1/1	1/1	0/1	3/3	0/1	0/1		1/1	1/1	0/1	2/3
Fusid -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	0/1	0/0	0/1		0/1	0/0	0/1	1/1	0/1
ERY -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	0/1	0/0	0/1	0/0	0/1	0/0	1/1	0/1	0/1
CIP -	0/3	1/3	0/3	0/3	1/3	1/3	1/3	-1/3	0/3	1/1	1/1	0/0	1/1	0/0	0/0	0/0	0/0	3/3	0/0	0/0	0/0	2/2
CHL -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/1	0/1	0/0	1/1	0/1	0/1
CXM -	0/1	0/1	0/1	0/1	0/1	1/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1	0/0	0/0	0/0	0/1
CAZ -	0/1	1/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	1/1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1	1/1	0/0	0/0	0/0
AMP -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	1/1	0/0	0/0	0/1	0/0	0/0	0/0	0/0	0/1
AMK -	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/0	0/0	1/1	0/0	0/0	0/1	0/0	0/0	0/0	0/0
Nosocomial -	0/5	0/5	-1/5	0/5	-1/5	0/5	5/5	4/5		0/1	0/1	1/1	0/1	0/1	0/3	0/1	0/1	0/5	0/1	0/1	0/1	0/3
Polymicrobial culture -	0/5	0/5	0/5	1/5	0/5	0/5	0/5	4/5	0/1	0/1	0/1	0/1	0/1	-1/3	0/1	0/1	0/5	0/1	0/1	0/1	0/1	0/3
Hospitalized -	0/5	0/5	5/5	5/5	3/5	5/5		0/5	5/5	0/1	0/1	0/1	0/1	1/3	0/1	0/1	1/5	0/1	1/1	0/1	0/1	0/3
T.F.other -	-3/5	2/5	0/0	0/0	0/0		5/5	0/5	0/5	0/1	0/1	0/1	1/1	1/3	0/1	0/1	1/5	0/1	0/1	0/1	1/3	
T.F.fluoroquinolone -	0/5	1/5	0/0	0/0	0/0	0/0	3/5	0/5	-1/5	0/1	0/1	0/1	0/1	1/3	0/1	0/1	0/5	0/1	1/1	0/1	0/3	
T.F.betalactam -	-1/5	2/5	0/0	0/0	0/0	0/0	5/5	1/5	0/5	0/1	0/1	0/1	0/1	0/3	0/1	0/1	0/5	0/1	0/1	0/1	0/3	
T.F.aminoglycoside -	0/5	3/5	0/0	0/0	0/0	5/5	0/5	-1/5	0/1	0/1	0/1	0/1	0/1	0/3	0/1	0/1	1/5	0/1	0/1	0/1	0/3	
Sex -	-1/5		3/5	2/5	1/5	2/5	0/5	0/5	0/5	0/1	0/1	1/1	0/1	0/1	1/3	0/1	0/1	0/5	0/1	0/1	0/1	0/3
Age -	-1/5	0/5	-1/5	0/5	0/5	-3/5	0/5	0/5	0/5	0/1	0/1	0/1	0/1	0/3	0/1	0/1	0/5	0/1	0/1	0/1	0/1	0/3

